- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01213992
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD (PK-CKD-03)
November 13, 2013 updated by: Pharmacosmos A/S
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-Dialysis Dependent Chronic Kidney Disease (PK-CKD-03)
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer® in patients suffering from Non-dialysis Dependent Chronic Kidney Disease.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women, aged more than 18 years.
- Weight above 50 kg.
- Subjects diagnosed with NDD-CKD with MDRD calculated eGFR between 15-59 mL/min.
- Hb < 11.0 g/dL.
- Either or both of the following iron stores indicators below target {Serum ferritin < 100 ug/l and Transferrin saturation (TfS) <20%}.
- Life expectancy beyond 12 months by Principal Investigator's judgement.
- Willingness to participate after informed consent.
Exclusion Criteria:
- Anaemia predominantly caused by factors other than renal impairment or iron deficiency (according to Principal Investigator s' judgment).
- Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
- Drug hypersensitivity (i.e. previous hypersensitivity to iron dextran or iron mono- or disaccharide complexes or any excipients of the study drug).
- Subjects with history of multiple allergies.
- Decompensated liver cirrhosis and hepatitis (alanine aminotransferase (ALT) > 3 times upper normal limit).
- History of Immunocompromise and/or history of Hepatitis B and/or C
- Active acute or chronic infections (assessed by clinical judgment), supplied with white blood cells (WBC) and C-reactive protein (CRP).
- Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, intrauterine devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
- Extensive active bleeding necessitating blood transfusion.
- Planned elective surgery during the study.
- Participation in any other clinical study within 3 months prior to screening.
- Untreated B12 or folate deficiency.
- Other I.V. or oral iron treatment or blood transfusion within 4 weeks prior to screening visit.
- ESA treatment within 8 weeks prior to screening visit.
- Serum Ferritin > 500 µg/L
- Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study or interfere with study drug evaluation. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Monofer® 500 mg
500 mg iron isomaltoside 1000
|
Single dose of 500 mg administered as a bolus undiluted over 2 min.
Single dose of 1000 mg infused over 15 min.
The infusion is diluted in 100mL 0,9% sodium chloride
|
ACTIVE_COMPARATOR: Monofer® 1000 mg
1000 mg iron isomaltoside 1000
|
Single dose of 500 mg administered as a bolus undiluted over 2 min.
Single dose of 1000 mg infused over 15 min.
The infusion is diluted in 100mL 0,9% sodium chloride
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total serum iron pharmakokinetic parameters
Time Frame: 30min, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours, 24 hours, 48 hours and 72 hours
|
30min, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours, 24 hours, 48 hours and 72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (ACTUAL)
October 1, 2012
Study Completion (ACTUAL)
November 1, 2012
Study Registration Dates
First Submitted
October 1, 2010
First Submitted That Met QC Criteria
October 1, 2010
First Posted (ESTIMATE)
October 4, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
November 14, 2013
Last Update Submitted That Met QC Criteria
November 13, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-Monofer-PK-CKD-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-dialysis Dependent Chronic Kidney Disease
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Active, not recruitingNon-Dialysis-Dependent Chronic Kidney DiseaseChina
-
Akebia TherapeuticsCompletedAnemia | Non-Dialysis-Dependent Chronic Kidney DiseaseUnited States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more
-
Akebia TherapeuticsCompletedAnemia | Non-Dialysis-Dependent Chronic Kidney DiseaseUnited States, Italy, Korea, Republic of, Australia, New Zealand, South Africa, United Kingdom, Spain, Ukraine, Hungary, Israel, Bulgaria, Russian Federation, Mexico, Poland, Brazil, Argentina, Malaysia, Puerto Rico, France
-
Akebia TherapeuticsCompletedAnemia | Non-dialysis Dependent Chronic Kidney DiseaseJapan
-
Pharmacosmos A/SCompletedChronic Kidney Disease Stage 5 (Dialysis Dependent)India
-
Akebia TherapeuticsCompletedAnemia | Dialysis-dependent Chronic Kidney DiseaseUnited States
-
Akebia TherapeuticsCompletedAnemia | Dialysis-Dependent Chronic Kidney DiseaseUnited States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
-
Akebia TherapeuticsCompletedAnemia | Dialysis-Dependent Chronic Kidney DiseaseUnited States, Italy, Korea, Republic of, Portugal, Russian Federation, Ukraine, Poland, Argentina, Brazil, Germany, Mexico
-
Akebia TherapeuticsTerminatedAnemia | Dialysis-Dependent Chronic Kidney DiseaseUnited States
-
Akebia TherapeuticsWithdrawnAnemia | Dialysis-Dependent Chronic Kidney DiseaseUnited States
Clinical Trials on Iron isomaltoside 1000
-
Pharmacosmos A/SCompleted
-
Pharmacosmos A/SCompletedInflammatory Bowel DiseaseDenmark
-
Pharmacosmos A/SCompletedPatients With Chemotherapy Induced Anemia (CIA)United States
-
Seoul National University HospitalCompletedAnemia | Knee ArthropathyKorea, Republic of
-
Pharmacosmos UK LtdBioStataCompletedIron Deficiency AnaemiaUnited Kingdom
-
Pharmacosmos A/SBioStataCompletedIron Deficiency AnemiaDenmark
-
University of MalayaRecruitingAnemia | Post Partum HemorrhageMalaysia
-
Pharmacosmos A/SBioStataCompletedAnaemia in Chronic Kidney DiseaseSweden, United Kingdom
-
Pharmacosmos A/SCompleted
-
Pharmacosmos A/SCompletedAnemia | Iron Metabolism Disorders | Deficiency Diseases | Anemia, Iron Deficiency | Hematologic DiseaseJapan